The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Congenital Dyserythropoietic Anemia: Diagnosis and Multidisciplinary Management

Rare hereditary anemias characterized by ineffective erythropoiesis with morphologically abnormal erythroblasts requiring genetic testing and individualized care

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Congenital Dyserythropoietic Anemia: Diagnosis and Multidisciplinary Management?

Congenital dyserythropoietic anemias represent group of rare hereditary disorders with ineffective erythropoiesis and abnormal erythroblast morphology.

CDA-I caused by CDAN1 or C15ORF41 mutations features megaloblastoid changes and internuclear chromatin bridges.

CDA-II SEC23B mutations is most common form with bi- or multinucleated late erythroblasts and acidified serum lysis test positivity.

CDA-III caused by KIF23 mutations features giant multinucleated erythroblasts with autosomal dominant inheritance.

Genomic sequencing has identified additional CDA forms with KLF1, GATA1 and other transcription factor mutations expanding spectrum.

Symptoms

Chronic anemia with hemoglobin typically 8-12 g/dL though severity varies between subtypes and individuals.
Jaundice from ineffective erythropoiesis with elevated unconjugated bilirubin and mild scleral icterus.
Splenomegaly is common with secondary hypersplenism contributing to cytopenias in some patients.
Iron overload develops without transfusions through suppressed hepcidin causing secondary hemochromatosis.
Fatigue, exercise intolerance, growth failure in children reflect chronic anemia impact on quality of life.

Risk Factors

Family history with autosomal recessive inheritance for CDA-I and CDA-II or autosomal dominant for CDA-III.
Specific genetic mutations identified through targeted sequencing or whole exome sequencing approach.
Mediterranean and Middle Eastern populations have higher CDA-II prevalence reflecting founder effects.
Iron overload risk persists without transfusion requirements unlike thalassemia making early monitoring critical.
Pregnancy complications including worsening anemia and fetal complications require specialized care.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Chronic anemia with elevated unconjugated bilirubin and reticulocytopenia inconsistent with severity warrants hematology evaluation.
  • Family history of CDA or unexplained chronic anemia with iron overload prompts diagnostic workup.
  • Bone marrow examination demonstrating characteristic erythroblast abnormalities and genetic confirmation establishes diagnosis.
  • Iron studies including ferritin, transferrin saturation, hepatic MRI for iron quantification guide chelation needs.
  • Multidisciplinary care including hematology, hepatology, cardiology, endocrinology for iron-related complications optimizes outcomes.

Treatment Methods

01
Supportive care with red blood cell transfusion in symptomatic anemia though most CDAs are not transfusion-dependent.
02
Iron chelation therapy with deferasirox or deferoxamine when ferritin exceeds 1000 ng/mL or hepatic iron accumulates.
03
Splenectomy in CDA-II with significant hypersplenism may improve hemoglobin in selected cases.
04
Interferon-alpha specifically for CDA-I demonstrates response in some patients improving anemia and reducing transfusion needs.
05
Allogeneic hematopoietic stem cell transplantation considered for severe transfusion-dependent disease, comprehensive supportive care including iron monitoring, hepatic surveillance, cardiac assessment, endocrine evaluation, growth monitoring in pediatric patients, family screening, genetic counseling, and treatment of complications optimizes outcomes for these rare hereditary anemias.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.